Med BioGene Inc (TSXV: MBI-H) has seen significant price movement this week, prompting a closer look at its current position and market sentiment.
This week, Med BioGene Inc. experienced a notable decline in its stock price, closing at C$0.02, a drop of 33.33% both for the day and the week. With limited recent news and a small market capitalization, let's explore the technical indicators and market context surrounding MBI-H.
Investor takeaway: Investors should be cautious given the high volatility and recent price drops. The lack of news and limited trading volume may indicate a lack of investor interest or confidence in the company's prospects.
Advertisement
Med BioGene Inc
MBI-H.V
MBI-H.V
Med BioGene Inc
WealthAwesomeMarket cap
$431,445
P/E
0.0x
52W high
$0.05
52W low
$0.02
1W change
-33.33%
Beta
1.54
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBI-H's historical volatility
30-Day Vol
146.6%
Annualized
90-Day Vol
193.5%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.01 – C$0.03 |
| 60 trading days | C$0.02 | C$0.01 – C$0.04 |
| 90 trading days | C$0.02 | C$0.01 – C$0.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Med BioGene Inc's stock price has decreased by 33.33% this week.
Advertisement
With a current market capitalization of approximately C$431,445 and a 52-week trading range of C$0.02 to C$0.05, MBI-H is operating at the lower end of its historical range.
Bull case
If Med BioGene can successfully leverage its GeneFX Lung™ test and secure partnerships or regulatory approvals, there is potential for future growth as the healthcare sector continues to innovate. This could open doors for new opportunities and increase investor interest.
Bear case
The significant price drop and low trading volume suggest a lack of market confidence. Additionally, the company's small size and limited coverage may hinder its ability to attract new investors. Without a solid foundation of support, Med BioGene may struggle to regain momentum.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
